Custom Cones USA Reveals Top 100 Pre-Roll Brands in the Country Highlighting Market Trends and Jeeter's Dominance
SEATTLE, June 11, 2025 (GLOBE NEWSWIRE) —
Custom Cones USA
, the cannabis industry's premier partner for pre-roll production, has released its
inaugural Top 100 Pre-Roll Brands report
. Developed in partnership with cannabis data firm
Headset
, the report offers a first-ever national ranking of the industry's pre-roll category. The report is based on sales data from 13 state markets and shows a $3.1 billion pre-roll market in 2024, with more than 316 million units sold and California-based
Jeeter
leading the pack with a commanding 8% market share.
Jeeter alone brought in $245 million in sales last year, more than double the revenue of its closest competitor, with consumers consistently choosing the brand's premium infused pre-rolls —averaging $24.62 per unit—over lower-priced options.
'Jeeter's success story represents the evolution of pre-rolls from commodity products to premium experiences,' said Harrison Bard, CEO of
Custom Cones USA
. 'Their $245 million revenue—more than double their closest competitor—shows how innovation in infused products can create market leadership as their demand continues to grow.'
The Top 10 brands account for 21.5% of total U.S. pre-roll sales, indicating a maturing market with increasing consolidation at the top. Fellow California heavyweight cannabis brand
STIIIZY
ranked second with $110.5 million in sales, while
Dogwalkers
secured third at $77 million.
The report also sheds light on two distinct winning strategies: high-end, infused offerings from brands like Jeeter and
Lowell Herb Co
., and low-cost, high-volume sales from value leaders like Michigan-based
Dragonfly Cannabis
, which sold 12.3 million units at an average price of just $2.38—the most units of any brand in the country.
Digital presence also proved to be a key growth driver. Using a proprietary 'Social Score' metric across Instagram, LinkedIn and brand websites, Custom Cones USA found that brands with higher engagement like
Cookies
and
Cheech & Chong's
often enjoyed stronger market performance, but this is not always the case.
The report also highlights notable regional patterns:
'The pre-roll market continues to evolve into a sophisticated category driving cannabis growth and innovation,' noted Bard. 'With $3.1 billion in sales and continued state-by-state legalization, we expect this segment to continue to grow in popularity for years to come.'
The full Top 100 report includes detailed data on pricing, unit volume, regional reach and digital presence. A condensed version is available for media, along with visual assets and analyst interviews upon request.
About Custom Cones USA
Founded in 2017 by Harrison Bard and Fredrik Rading, Custom Cones USA is a leading pre-roll resource in the cannabis industry. The team has a wealth of knowledge about all aspects of pre-roll manufacturing and the entire pre-roll sector of the cannabis space. From
custom-branded pre-rolled cones
and
wholesale bulk cones
, to completely
customized pre-roll packaging
projects and
pre-roll machines
, they offer expertise and solutions to companies big and small in all sectors of the pre-roll space. Custom Cones USA has brought their top quality rolling papers to the consumer through its brand
DaySavers
, which is the most compliant and transparent smoking accessories brand on the market, by holding itself to the same compliance standards as regulated cannabis companies. Learn more at
CustomConesUSA.com
.
Media Contact
Molly Sposato
Grasslands: A Journalism-Minded Agency
molly@mygrasslands.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Meta and energy company announce plans for geothermal plant in New Mexico
Meta and a California-based geothermal energy company announced plans on Thursday to build a geothermal power plant in Northwestern New Mexico, as Gov. Michelle Lujan Grisham and other officials touted a report outlining how the state has the resources to produce substantial geothermal power. Meta, the parent company of Facebook, and XGS Energy aim to build a geothermal energy site capable of producing 150 megawatts at a location that has not yet been named. A recent report indicates the Santa Fe region, as well as portions of Sandoval and Tao counties, are particularly well positioned to produce geothermal energy. "We sit on, no kidding, one of the best dry hot rock energy resources not just in Western United States but in the entire world," said Josh Prueher, XGS Energy CEO, during a news conference at the state Capitol, flanked by Lujan Grisham. "The statistics are staggering." Meta in 2019 opened a sprawling data center in Los Lunas where the tech giant stores videos, photos and other media that its billions of users have posted to the social network. It is unclear whether the new geothermal power plant would support its existing footprint in New Mexico and the Southwest or a future expansion. Prueher said XGS is considering public, private and tribal lands to site the planned plant and is engaged with landowners in each of those categories. Asked whether Sandoval, Santa Fe and Taos counties might be potential locations, Prueher said they could be. The 200-page "The Future of Geothermal in New Mexico" report, published by Project InnerSpace in collaboration with New Mexico Tech and the New Mexico Bureau of Geology and Mineral Resources, notes the potential for 163 gigawatts of geothermal power to be generated in the state. The Future of Geothermal in New Mexico The vast subsurface heat present in the state could help boost the Land of Enchantment's clean energy future, advocates of the project say. "It's a big damn deal," Lujan Grisham said, praising the economic and job creation impact the project could have. Geothermal resources, typically reservoirs of hot water that exist at various temperatures, generate renewable energy from hot water sources deep beneath Earth's surface. Most of the geothermal power plants in the U.S. are in western states and Hawaii, according to the U.S. Energy Information Administration, where geothermal energy resources are close to the earth's surface. California generates the most electricity from geothermal energy. Lujan Grisham said the project is not receiving state money at this time. The geothermal power plant in Northwestern New Mexico would be the second in the state, with one such power plant already in operation in Hidalgo County. This is a developing story and will be updated.
Yahoo
15 minutes ago
- Yahoo
ADM sets off 'frenzy' in US soybean market ahead of new biofuel blend rule
By Tom Polansek and Karl Plume CHICAGO (Reuters) -Archer-Daniels-Midland, a major U.S. soybean crusher and biofuel producer, slashed its bids to buy the oilseed this week ahead of an expected Trump administration announcement on biofuel blending requirements, a primary driver of demand for soybean oil. Processors such as Chicago-based ADM have been waiting for the U.S. Environmental Protection Agency's decision on blending requirements for months as they grapple with slumping crush margins and abundant soybean stocks. Reuters reported on Thursday that the EPA is expected to propose blending requirements below industry recommendations on Friday, leading to lower-than-expected demand for soyoil to be used in biofuels. ADM said in an emailed statement to Reuters on Thursday that it does not have insight around the pending blending announcement beyond publicly available information and that it independently sets its basis bids, which is the difference between futures and a local cash price to take possession of the grain immediately. The company on Wednesday rolled its cash basis bid at its flagship Decatur, Illinois, facility to 20 cents below the Chicago Board of Trade November soybean futures price from 22 cents over July futures. The roll to November futures, which closed at a 15-cent discount to July on Thursday, lowered the local cash price by about 60 cents a bushel, representing an unusually sharp 6.5% drop in the price offered to farmers. ADM also rolled basis bids at its other crushing facilities, and some rival processors, including Cargill, followed ADM on Thursday. Other processors kept their basis bids against the July futures contract, but lowered basis values by up to 15 cents. "ADM Decatur put the bean market in a frenzy," agriculture trading company John Stewart and Associates said in a note. Falling basis values reflect expectations for a large autumn harvest and weak demand that has eroded processing margins for companies that crush beans into soymeal livestock feed and soyoil used for cooking and producing biofuels. Crush margins have struggled as a recent jump in U.S. processing capacity has swelled available supplies of meal and oil and pressured prices for the soy products. Tariff worries and unclear U.S. biofuels policies have stoked further unease among crushers and biofuel makers, and some biodiesel producers have scaled back or idled plants. ADM said in April it would permanently close a South Carolina soybean processing plant to cut costs. "Cash crush margins stink, and there is a bunch of downtime scheduled for July," said Charlie Sernatinger, executive vice president for Marex Capital Markets. Diana Klemme, vice president of Grain Service Corp in Atlanta, which serves agricultural hedgers in the futures markets, sent an alert to customers after seeing ADM's bid adjustments. She said that she had never seen a move to new-crop basis levels in June in more than 50 years in the grain business. "I said check your markets carefully because ADM just dropped all their bids 40-75 cents a bushel and went to new-crop values," Klemme said. The November futures contract represents the autumn harvest price, or the new crop. Farmers have been reluctant to sell crops to processors because they want higher prices, while processors avoided raising bids to protect their thin margins.
Yahoo
25 minutes ago
- Yahoo
Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025
Seven months after the completion of dosing: 41% of patients (150 mg Q4W) continue to experience complete response (UAS7=0) 48% of patients (150 mg Q4W) report that CSU no longer impacts their quality of life (DLQI=0/1) KIT related tolerability events demonstrated to be reversible Enrollment to Phase 3 CSU trials ongoing Company to host webcast today at 6:00 pm ET HAMPTON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating profound, sustained complete response and improved quality of life at 76 weeks, 7 months after the completion of dosing with barzolvolimab in chronic spontaneous urticaria (CSU), an immune-related condition driven by mast cell activation. Barzolvolimab specifically targets mast cells by binding the receptor tyrosine kinase KIT with high specificity and potently inhibiting its activity, which is required for mast cell function and survival. The data are being presented in a late breaking oral presentation (#100227) at the EAACI Congress 2025. The Company previously announced that this Phase 2 study of barzolvolimab in patients with moderate to severe CSU refractory to antihistamines, including patients with biologic-refractory disease, met its primary endpoint—a significant improvement in UAS7 compared to placebo at 12 weeks—across all dose groups tested. Barzolvolimab also demonstrated rapid, profound complete response rates (UAS7=0; no itch/no hives) in up to 51% of patients at 12 weeks, which continued to deepen over 52 weeks of active therapy to up to 71% of patients. Seven months after completion of dosing, patients continue to experience profound clinical benefit, with up to 41% of patients reporting a complete response at 76 weeks and 48% of patients reporting that their disease no longer impacts their quality of life. Barzolvolimab demonstrated a well tolerated safety profile throughout the study. 'In this large Phase 2 study, patients on barzolvolimab experienced rapid, profound, durable complete response which correlated with meaningful improvements in quality of life—the goal of treatment for patients and physicians,' said Martin Metz, M.D., Professor, Department of Dermatology and Allergy, Head of Translational Research and Deputy Head of Clinical Trials at Charité – Universitätsmedizin in Berlin and the lead investigator of the study. 'By addressing the root driver of chronic spontaneous urticaria, the mast cell, barzolvolimab provided meaningful clinical benefit to more than 90% of the patients on study, including patients with severe disease refractory to omalizumab, and demonstrated a level of sustained complete response after the completion of active therapy that is unprecedented in CSU. Importantly, across this large, 76 week Phase 2 trial, barzolvolimab also presented a favorable safety profile, further supporting barzolvolimab's significant potential to become a transformative treatment option for patients suffering from this often very severe and debilitating disease.' Data highlights at 76 weeks (7 months/28 weeks after completion of barzolvolimab treatment) Rapid, profound improvements in UAS7 (weekly urticaria activity score) were reported as early as one week after dosing. Barzolvolimab achieved the primary efficacy endpoint, a statistically significant mean change from baseline to Week 12 in UAS7 (weekly urticaria activity score) compared to placebo, at all dose levels. These improvements were sustained or deepened at Week 52 and continued to Week 76. UAS7 mean change from baseline at Week 76 was -20.42 for patients treated with 150 mg Q4W and -21.10 for patients treated with 300 mg Q8W. 41% of patients treated with barzolvolimab 150 mg Q4W and 35% of patients treated with 300 mg Q8W had a complete response (no itch/hives; UAS7=0) at Week 76. 56% of patients treated with barzolvolimab 150 mg Q4W and 47% of patients treated with 300 mg Q8W had well controlled disease (UAS7≤6) at Week 76. 48% of patients treated with barzolvolimab 150 mg Q4W and 40% of patients treated with 300 mg Q8W reported that CSU had no impact on their quality of life at 76 weeks as measured by the Dermatology Life Quality Index (DLQI). Current clinical guidelines recommend complete response (UAS7=0) as the goal of treatment1 and achieving complete response is directly correlated to the greatest improvements in quality of life for patients2. These robust responses and improvements in quality of life were observed regardless of prior omalizumab experience. Barzolvolimab was well tolerated with a favorable safety profile through 76 weeks. The most common adverse events were grade 1 (mild), mechanism related (KIT) and reversible. No new safety signals were identified during the follow-up period. As previously disclosed, neutropenia events resolved rapidly and while still receiving barzolvolimab treatment and there was no association between neutropenia and infections. As expected, neutrophil counts returned to baseline following the completion of barzolvolimab treatment and the mild hair color changes and skin hypopigmentation observed on study were demonstrated to be reversible following discontinuation of treatment. 'At every analysis across multiple endpoints in this Phase 2 study, barzolvolimab has demonstrated best in disease data, suggesting barzolvolimab holds great promise as a transformational treatment for patients suffering from CSU— a disease of misery that often impacts all aspects of patients' lives,' said Diane C. Young, M.D., Senior Vice President and Chief Medical Officer of Celldex. 'On behalf of Celldex, I want to thank the patients and physicians who participated in this study. We remain diligently focused on executing across our clinical trials to bring this potential important new medicine to patients.' Results presented at the EAACI Congress 2025 are available on the "Publications' page of the "Science" section of the Celldex website. 1Zuberbier T, et al. Allergy, 2022; 2Kolkhir P, et al. JACI, 2023 Webcast The Company will host a conference call/webcast today to discuss the results at 6:00 pm ET. To access the live and archived webcast, please visit the Events section on the Investor Relations page of Celldex's website. Parties interested in participating via telephone may register here to receive the dial-in numbers and unique PIN to seamlessly access the call. Otherwise please access the listen-only webcast link. The archived webcast will be available for a limited time on the Company's website. About BarzolvolimabBarzolvolimab is a humanized monoclonal antibody that binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. KIT is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival and activity of mast cells. In certain inflammatory diseases, such as chronic urticaria, mast cell activation plays a central role in the onset and progression of the disease. Barzolvolimab is currently being studied in chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), prurigo nodularis (PN), eosinophilic esophagitis (EOE) and atopic dermatitis (AD), with additional indications planned for the future. About the Phase 2 CSU StudyThe randomized, double-blind, placebo-controlled, parallel group Phase 2 study evaluated the efficacy and safety profile of multiple dose regimens of barzolvolimab in patients with CSU who remain symptomatic despite antihistamine therapy, to determine the optimal dosing strategy. 208 patients were randomly assigned on a 1:1:1:1 ratio to receive subcutaneous injections of barzolvolimab at 75 mg every 4 weeks, 150 mg every 4 weeks, 300 mg every 8 weeks or placebo during a 16-week placebo-controlled treatment period. After 16 weeks, patients then entered a 36-week active treatment period, in which patients receiving placebo or the 75 mg dose were randomized to receive barzolvolimab 150 mg every 4 weeks or 300 mg every 8 weeks; patients already randomized to the 150 mg and 300 mg treatment arms remained on the same regimen as during the placebo-controlled treatment period. After 52 weeks, patients enter a follow-up period for an additional 24 weeks. Barzolvolimab achieved the primary efficacy endpoint of the study—a statistically significant mean change from baseline to week 12 in UAS7 (weekly urticaria activity score) compared to placebo at all dose levels. For additional information on this trial (NCT05368285), please visit About the Phase 3 ProgramCelldex is currently conducting a global Phase 3 Program for barzolvolimab in CSU, consisting of two Phase 3 trials (EMBARQ-CSU1; NCT06445023 and EMBARQ-CSU2; NCT06455202) designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic despite H1 antihistamine treatment. The studies also include patients who remain symptomatic after treatment with biologics. Enrollment is underway. About Chronic Spontaneous Urticaria (CSU)CSU is characterized by the occurrence of hives or wheals for 6 weeks or longer without identifiable specific triggers or causes. The activation of the mast cells in the skin (release of histamines, leukotrienes, chemokines) results in episodes of itchy hives, swelling and inflammation of the skin that can go on for years or even decades. Current therapies provide symptomatic relief only in some patients. About Celldex Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune Forward Looking StatementThis release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of Company drug candidates, including barzolvolimab (also referred to as CDX-0159), in current or future indications; the uncertainties inherent in clinical testing and accruing patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products at varying stages of development; the availability, cost, delivery and quality of clinical materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; our ability to continue to obtain capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; and other factors listed under "Risk Factors" in our annual report on Form 10-K and quarterly reports on Form 10-Q. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise. Company ContactSarah CavanaughSenior Vice President, Corporate Affairs & Administration(508) 864-8337scavanaugh@ Patrick TillMeru Advisors(484) 788-8560ptill@
